30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

First Look at 1Q11 Results: NuVasive

$124.5MM, +14% (Biologics $22.6MM; Lumbar fusion +10%)
* Pricing very similar to past couple of quarters
* Continuing payor pushback on lumbar fusion, but landscape is stabilizing
* Of surveyed surgeons, 60% of respondents believe that the majority of cases actually meet insurance policy guidelines, and ~60% of respondents successfully overturned preauthorization denials on 1st appeal
* Still taking share in lateral fusion market
* Launching MaXcess 4 (surgical access system) in 2Q
* Opened office in Puerto Rico, on track to open Tokyo office later this year
* Global sales force >300 to date